Glucose disturbances in first-episode drug-naïve schizophrenia: Relationship to psychopathology

Psychoneuroendocrinology

Volumn 62, Issue , 2015, Pages 376-380

  Zhang, Xiang Yang ^a,b   Chen, Da Chun ^a   Tan, Yun Long ^a   An, Hui Mei ^a   Zunta Soares, Giovana B ^b   Huang, Xu Feng ^c   Soares, Jair C ^b  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Drug na ve; First episode; Glycometabolism; Lipid profile; Psychopathology; Schizophrenia

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; INSULIN; LIPID;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SYNDROME DELINEATION; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84947442335     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.09.005     Document Type: Article

References (24)

1. Alkelai A., Greenbaum L., Lupoli S., Kohn Y., Sarner-Kanyas K., Ben-Asher E., Lancet D., Macciardi F., Lerer B. Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One 2012, 7:e29228.
2. Arranz B., Rosel P., Ramírez N., Dueñas R., Fernández P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65:1335-1342.
3. Baptista T., Lacruz A., Paez X., Hernandez L., Beaulieu S. The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?. Eur. J. Pharmacol. 2002, 447:91-98.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 1995, 57:289-300.
5. Britvic D., Maric N.P., Doknic M., Pekic S., Andric S., Jasovic-Gasic M., Popovic V. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatr. Danub. 2013, 25:410-415.
6. Chen S., Broqueres-You D., Yang G., Wang Z., Li Y., Wang N., Zhang X., Yang F., Tan Y. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013, 210:825-829.
7. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., Malaspina D. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003, 29:671-692.
8. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194:434-438.
9. Garcia-Tornadu I., Ornstein A.M., Chamson-Reig A., Wheeler M.B., Hill D.J., Arany E., Rubinstein M., Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010, 151:1441-1450.
10. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., Wayland M.T., Umrania Y., Herberth M., Koethe D., van Beveren J.M., Rothermundt M., McAllister G., Leweke F.M., Steiner J., Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol. Psychiatry 2010, 15:118-119.
11. Guest P.C., Schwarz E., Krishnamurthy D., Harris L.W., Leweke F.M., Rothermundt M., van Beveren N.J., Spain M., Barnes A., Steiner J., Rahmoune H., Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36:1092-1096.
12. Harris L.W., Guest P.C., Wayland M.T., Umrania Y., Krishnamurthy D., Rahmoune H., Bahn S. Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology 2013, 38:752-766.
13. Lin P.I., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 2010, 123:234-243.
14. Lopuszańska U.J., Skorzyńska-Dziduszko K., Lupa-Zatwarnicka K., Makara-Studzińska M. Mental illness and metabolic syndrome?a literature review. Ann. Agric. Environ. Med. 2014, 21:815-821.
15. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39:295-305.
16. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., Baptista T., Malla A., Joober R. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr. Res. 2008, 102:329-336.
17. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Med. 2007, 24:481-485.
18. Stubbs B., Vancampfort D., De Hert M., Mitchell A.J. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr. Scand. 2015, 132(2):144-157.
19. Toalson P., Saeeduddin A., Hardy T., Kabinoff G. The metabolic syndrome in patients with severe mental illness. J. Clin. Psychiatry 2004, 6:152-158.
20. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., Shetty K.T. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 2007, 164:1557-1560.
21. Walder D.J., Walker E.F., Lewine R.J. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry 2000, 48:1121-1132.
22. Wu X., Huang Z., Wu R., Zhong Z., Wei Q., Wang H., Diao F., Wang J., Zheng L., Zhao J., Zhang J. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr. Res. 2013, 150:157-162.
23. Zhang X., Hui L., Liu Y., Wang Z.Q., You Y., Miao L.N., Sun S.L., Guan S.L., Xiang Y., Kosten T.R., Zhang X.Y. The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J. Clin. Psychiatry 2013, 74:e287-e292.
24. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.